BIO Study On Follow-On Biologics Focuses On Trade-Off Between Savings And R&D
This article was originally published in The Pink Sheet Daily
Study extrapolates from CBO’s scoring of last year’s Senate bill to argue that “shorter exclusivity could lead to the worst of both worlds – fewer new biologics … and little savings.”
You may also be interested in...
Even without reimbursement changes, CBO estimates higher Medicare/Medicaid savings than in previous scoring of Senate bill.
Paper by AEI fellow Brill challenges the assumptions in the 16-year estimate from Duke's Grabowski.
Pink Sheet reporters and editor discuss the ramifications of the AstraZeneca vaccine trial hold and vaccine sponsors pledging to wait until the completion of Phase III before submitting applications, as well as efforts to extend the rare pediatric disease priority review voucher program.